common side effects of elinest
vulvovaginal candidiasis
breakthrough bleeding
glucose tolerance
headache
increased blood pressure
migraine
spotty menstruation
vaginitis
dizziness
other side effects
abdominal cramps
abdominal distention
acne vulgaris
breast changes
nausea
vomiting
comprehensive list of adverse effects
doctor if any of these
common side effects
acne
breast tenderness
enlargement
changes in appetite
changes in weight
dizziness
headache
mild hair loss
nausea
nervousness
stomach cramps
bloating
vaginal spotting
breakthrough bleeding
severe allergic reactions
rash
hives
itching
difficulty breathing
tightness in the chest
swelling of the mouth
face
lips
tongue
unusual hoarseness
absent menstrual period
breast discharge
breast lumps
calf
leg pain
swelling
tenderness
change in the amount of urine
chest pain
heaviness
confusion
coughing of blood
dark urine
fainting
mood changes
depression
migraines
numbness of an arm
leg
one-sided weakness
pale stools
recurring headache
dizziness
persistent vaginal spotting
severe pain
tenderness in the stomach
shortness of breath
speech
sudden severe headache
vomiting
swelling of the fingers
hands
legs
ankles
severe vaginal bleeding
unusual tiredness
weakness
vaginal irritation
discharge
change in secretions
vision changes
sudden vision loss
double vision
yellowing of the skin
eyes
fever
adverse effects
women on oral contraceptive combination products
relative excess
deficiency of the estrogen
progestin components of these formulations
following
frequent adverse effects by relative excess
deficiency of these components
progestin
acne
oily skinbreast tendernessdepressiontiredness
fatiguehair
appetiteweight
gaincholestatic jaundiceprogestin deficiency
late breakthrough bleedingamenorrheahypermenorrheaestrogen
nauseaheadachemelasmahypertensionbreast tendernessedemaestrogen deficiency
early/mid-cycle breakthrough
bleedingincreased spottinghypomenorrhea
women
taking oral contraceptive combinations
several non-contraceptive health benefits
benefits
protection
malignant neoplasms
endometrial carcinoma
ovarian cancer
addition
use of oral contraceptive combinations
frequency of benign breast tumors
ovarian cysts
ectopic pregnancy
menstrual irregularity
iron deficiency anemia
dysmenorrhea
pelvic inflammatory disease
number of studies
use of oral contraceptives
risk of ovarian cancer
risk of epithelial ovarian cancers
protection against ovarian cancer
years after discontinuation of oral contraceptives
long term use
years
risk of ovarian cancer
risk of endometrial cancer
protection
years after discontinuation
nulliparous women
higher risk for endometrial carcinoma than other women
incidence of hospitalization for pelvic inflammatory disease
women
taking oral contraceptives
reason for the decrease in the frequency
severity
pelvic inflammatory disease in women
taking oral contraceptives
recent studies
decrease in frequency of functional ovarian cysts
older formulations
women
taking newer low dose formulations
recent study
nurses
health study
long term use of oral contraceptives
long term risk for mortality
cases of oral contraceptive-induced esophageal ulceration
geographic tongue
recent studies
risk of gallbladder disease
common gastrointestinal side effect
nausea
treated women
first cycles of therapy
early reports
association between oral contraceptive use
gallbladder disease
world health organization committee
studies
weak association between long-term use of oral contraceptives
breast cancer
age
age
observed association
bias
development of new cases of cancer
accelerated growth
existing cancers
world health organization committee
increased risk of breast cancer in women over the age
taken oral contraceptives
addition
studies
use of oral contraceptives
specific groups of women
family history of breast cancer
lower risk
variations in the hormonal content of oral contraceptives
risk of breast cancer
studies
potential risk of cervical cancer in patients
taking oral contraceptives
large number of confounding factors
investigations into the epidemiology of this neoplasm
studies
women
taking oral contraceptives
increased risk of dysplasia
epidermoid carcinoma
adenocarcinoma of the cervix
other studies
association
oral contraceptive combinations
oncologic side effects
number of studies
possible relationship between the use of oral contraceptives
development of breast cancer
studies
reported conflicting results
committee of the world health organization
studies
risks of breast cancer
numerous studies
overall association between oral contraceptive use
risk of breast cancer
addition
same committee
possible relationship between oral contraceptive use
neoplasms of the uterine cervix
insufficient data
firm conclusions
effects
combined oral contraceptives on the risk of cervical adenocarcinoma
"
cardiovascular
side effects of the estrogen component of this combination drug
hypertension
significant blood pressure increases
women
receiving high-dose estrogen products
mcg
ethinyl estradiol
estrogens
edema
addition
exogenous estrogens
cardio-protective effects
causing
causing favorable changes in lipid profiles
beneficial effects
alterations in lipid profiles
exogenous progestins
detailed information
effects of oral contraceptive therapy on lipid metabolism
endocrine paragraph of this side effect monograph
early investigations of women
taking high dose estrogen combinations
mcg
ethinyl estradiol
such women
increased risk of cardiovascular complications
myocardial infarction
stroke
vascular thrombosis
including
venous thromboembolism
recent large investigations of women
taking low dose estrogen combinations
oral contraceptive use
increased risk of serious cardiovascular complications in healthy non smoking women
age
women
preexisting
preexisting systemic diseases
cardiovascular system
use of oral contraceptives
investigators
new low dose products
adverse effects on lipid metabolism
careful review of a woman
cardiovascular risk factors before a decision
oral contraceptive combinations
frequency of both subarachnoid hemorrhage
thrombotic stroke
investigators
women
taking oral contraceptive hormones
other investigators
risk of these effects for women
using newer low dose formulations
young women
underlying
underlying cardiovascular disease
other risk factors
metabolic effects
complex alterations in plasma lipid profiles
carbohydrate metabolism
addition
oral contraceptive use
conception delay
progestins
available oral contraceptive combinations
adverse effects on lipid profiles
progestins
antiestrogen
androgen effects
hdl
hdl
cholesterol levels
increase ldl cholesterol levels
estrogens in oral contraceptive combinations
opposing effects
alterations in lipid profiles
relative amount
potency of the specific estrogen
progestin in a
given product
norgestrel
potent progestin
antiestrogen
androgen effects
number of investigations
oral contraceptive combinations
glucose tolerance
recent studies with low dose preparations
glucose tolerance
oral contraceptive combinations
adverse effects of oral contraceptives on lipid levels
glucose tolerance
investigators
young diabetic women
existing
existing vascular disease
severe lipidemias
candidates for low dose
oral contraceptive combinations
close monitoring for adverse metabolic effects
hepatic side effects
focal nodular hyperplasia
intrahepatic cholestasis
liver cell adenomas
hepatic granulomas
hepatic hemangiomas
well-differentiated hepatocellular carcinomas
association with estrogen therapy
therapy with oral contraceptive combinations
rate of death
hepatocellular carcinoma in the united states
last years
time during which use of oral contraceptive hormones
committee of the world health organization
developing countries
hepatitis b virus infection
hepatocellular carcinoma
short term use of oral contraceptives
increased risk
data on the effects of long term use
recent italian case-control study of women with hepatocellular carcinoma
relative risk of hepatocellular carcinoma
oral contraceptive users
women
oral contraceptives
similar american case-control study
strong association between oral contraceptive use
hepatocellular carcinoma
observed association
actual number of cases of liver cancer in the united states
oral contraceptive use
findings
public health importance in the united states
other western nations
"
hematologic concern
risk of thromboembolism
use of exogenous estrogens
dose of exogenous estrogens
available preparations
risk of thromboembolism
most women
women
age
smoke
women with a history of previous thrombotic diseases
cases of venous thrombosis
pulmonary embolism
arterial thrombosis
previous thrombotic disease
contraindication
oral contraceptive combinations
common genitourinary side effect
breakthrough bleeding
spotting
first several cycles of oral contraceptive use
non-hormonal causes of such bleeding
women experience oligomenorrhea
amenorrhea
following termination
oral contraceptive use
psychiatric side effects
depression
precipitation of panic disorder
immunologic side effects
cases of oral contraceptive-induced systemic lupus erythematosus
case of fatal pulmonary venooclusive disease
oral contraceptive therapy
nervous system
side effects
chorea
association with oral contraceptives
ocular side effects
cases of retinal thrombosis
addition
manufacturers of oral contraceptive products
patients
changes in contact lens tolerance